This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.
Study Type
OBSERVATIONAL
Enrollment
1,408
Rituximab use in non-oncology indications
Chu De Clermont Ferrand; Hopital Gabriel Montpied
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
Centre Hospitalier Le Mans
Le Mans, France
Hopital Claude Huriez - CHU Lille
Lille, France
Hôpital Lapeyronie
Montpellier, France
CHU NANTES - Hôtel Dieu; Pharmacy
Percentage of Participants Aware of Known and Potential Risks of Infection Associated with Rituximab
Time frame: Up to 10 months
Percentage of Participants Using Rituximab Off-Label
Time frame: Up to 10 months
Disease Activity Score Based on 28 Joints (DAS28) for Participants with Rheumatoid Arthritis (RA)
Time frame: Up to 10 months
Percentage of Participants Who Received the Patient Alert Card (PAC)
Time frame: Up to 10 months
Percentage of Participants Who Read the PAC
Time frame: Up to 10 months
Percentage of Participants Who Received Additional Safety-Related Materials
Time frame: Up to 10 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Nantes, France
Hôpital Cochin
Paris, France
Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Centre François Magendie
Pessac, France
CHU Saint-Etienne, Hopital Bellevue
Saint-Etienne, France
CHU de Toulouse - Hôpital Purpan
Toulouse, France
...and 38 more locations